New Launch10 Nov 2025, 11:31 am
Emcure Pharma to Distribute Novo Nordisk's Semaglutide Injection for Weight Loss in India
AI Summary
Novo Nordisk India has partnered with Emcure Pharma to commercialize Poviztra®, a second brand of Wegovy® (semaglutide injection 2.4 mg), in India. This partnership aims to make innovative semaglutide molecule accessible to more people living with overweight and obesity in India. Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra® in India.
Key Highlights
- Emcure Pharma becomes the first Indian company with exclusive rights to distribute and commercialise Poviztra®, semaglutide injection 2.4 mg, for weight loss in India.
- This partnership is part of Novo Nordisk's efforts to make its innovative semaglutide molecule accessible to a greater number of people living with overweight and obesity in India.
- Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra®, semaglutide injection 2.4 mg, in India.
- Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has strong clinical data and has been extensively studied across multiple obesity trials.
- India has nearly 254 million people living with generalised obesity and another 351 million living with abdominal obesity.